Skip to main content
. 2024 Oct 22;16(21):3558. doi: 10.3390/cancers16213558

Figure 1.

Figure 1

Survival outcomes. Kaplan–Meier estimates for (A) time on treatment (TOT), (B) recurrence-free survival (RFS), (C) distant metastasis free survival (DMFS) and (D) time to next treatment (TTNT) for patients treated with adjuvant pembrolizumab. CI: confidence interval, NR: not reached.